Literature DB >> 23229762

Primary intracranial soft tissue sarcoma in children and adolescents: a cooperative analysis of the European CWS and HIT study groups.

Martin Benesch1, André O von Bueren, Tobias Dantonello, Katja von Hoff, Torsten Pietsch, Ivo Leuschner, Alexander Claviez, Uta Bierbach, Gabriele Kropshofer, Rudolf Korinthenberg, Norbert Graf, Meinolf Suttorp, Rolf Dieter Kortmann, Carsten Friedrich, Nicolas von der Weid, Peter Kaatsch, Thomas Klingebiel, Ewa Koscielniak, Stefan Rutkowski.   

Abstract

Purely intracranial soft tissue sarcomas (ISTS) are very rare among children. A retrospective database analysis of the Cooperative Weichteilsarkom Studiengruppe (CWS) and brain tumor (HIT) registries was conducted to describe treatment and long-term outcome of children and adolescents with ISTS. Nineteen patients from Germany, Austria and Switzerland were reported between 1988 and 2009. Median age at diagnosis was 9.7 years (range, 0.5-17.8). Central pathological review was performed in 17 patients. Eleven patients underwent a total and five a subtotal tumor resection. A biopsy was done in one patient. In two patients no data concerning extent of initial resection was available. Radiotherapy was performed in 15 patients (first-line, n = 11; following progression, n = 4). All but one patient received chemotherapy (first-line, n = 7, following progression, n = 5; first-line and following progression, n = 6). With a median follow-up of 5.8 years (range, 0.6-19.8) ten patients were alive in either first or second complete remission. Seven patients died due to relapse or progression and two were alive with progressive disease. Estimated progression-free and overall survival at 5 years were 47 % (±12 %) and 74 % (±10 %), respectively. About 50 % of patients with ISTS remain relapse-free after 5 years. Multimodality treatment including complete tumor resection and radio-/chemotherapy is required to achieve sustained tumor control in patients with ISTS. Early initiation of postoperative non-surgical treatment seems to be important to prevent recurrence. Due to the intracranial localization local therapy should follow the recommendations used in brain tumors rather than in soft tissue sarcomas, whereas chemotherapy should be guided by histological subtype.

Entities:  

Mesh:

Year:  2012        PMID: 23229762     DOI: 10.1007/s11060-012-1020-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  24 in total

1.  Treatment of young children with localized medulloblastoma by chemotherapy alone: results of the prospective, multicenter trial HIT 2000 confirming the prognostic impact of histology.

Authors:  André O von Bueren; Katja von Hoff; Torsten Pietsch; Nicolas U Gerber; Monika Warmuth-Metz; Frank Deinlein; Isabella Zwiener; Andreas Faldum; Gudrun Fleischhack; Martin Benesch; Juergen Krauss; Joachim Kuehl; Rolf D Kortmann; Stefan Rutkowski
Journal:  Neuro Oncol       Date:  2011-06       Impact factor: 12.300

Review 2.  Clinical application of molecular pathology in sarcomas.

Authors:  Salvatore Romeo; Angelo P Dei Tos
Journal:  Curr Opin Oncol       Date:  2011-07       Impact factor: 3.645

3.  Results of treatment for soft tissue sarcoma in childhood and adolescence: a final report of the German Cooperative Soft Tissue Sarcoma Study CWS-86.

Authors:  E Koscielniak; D Harms; G Henze; H Jürgens; H Gadner; M Herbst; T Klingebiel; B F Schmidt; M Morgan; R Knietig; J Treuner
Journal:  J Clin Oncol       Date:  1999-12       Impact factor: 44.544

4.  Primary intracranial fibrosarcoma.

Authors:  Gianni Bisogno; Jelena Roganovic; Modesto Carli; Giovanni Scarzello; Milena Calderone; Roberto Faggin; Giorgio Perilongo
Journal:  Childs Nerv Syst       Date:  2002-08-15       Impact factor: 1.475

5.  Primary parafalcine chondrosarcoma in a child.

Authors:  P C Gerszten; I F Pollack; R L Hamilton
Journal:  Acta Neuropathol       Date:  1998-01       Impact factor: 17.088

6.  Successful treatment of a child with a primary intracranial rhabdomyosarcoma with chemotherapy and radiation therapy.

Authors:  Gregory Michael Taylor Guilcher; Glenda Hendson; Karen Goddard; Paul Steinbok; Mason Bond
Journal:  J Neurooncol       Date:  2007-06-20       Impact factor: 4.130

7.  Intensive chemotherapy improves survival in pediatric high-grade glioma after gross total resection: results of the HIT-GBM-C protocol.

Authors:  Johannes E A Wolff; Pablo Hernaiz Driever; Bernhard Erdlenbruch; Rolf D Kortmann; Stefan Rutkowski; Torsten Pietsch; Crystal Parker; Monica Warmuth Metz; Astrid Gnekow; Christof M Kramm
Journal:  Cancer       Date:  2010-02-01       Impact factor: 6.860

8.  Primary cerebral leiomyosarcoma in a child.

Authors:  Boris P Eckhardt; Sebastian Brandner; Christoph L Zollikofer; Klaus U Wentz
Journal:  Pediatr Radiol       Date:  2004-04-01

Review 9.  Meningeal mesenchymal chondrosarcoma: report of 8 cases with review of the literature.

Authors:  B W Scheithauer; L J Rubinstein
Journal:  Cancer       Date:  1978-12       Impact factor: 6.860

10.  Primary intracranial rhabdomyosarcoma.

Authors:  J J Olson; A H Menezes; J C Godersky; J M Lobosky; M Hart
Journal:  Neurosurgery       Date:  1985-07       Impact factor: 4.654

View more
  3 in total

Review 1.  Primary intracranial soft tissue sarcomas in children, adolescents, and young adults: single institution experience and review of the literature.

Authors:  Ossama M Maher; Soumen Khatua; Devashis Mukherjee; Adriana Olar; Alexander Lazar; Raja Luthra; Diane Liu; Jimin Wu; Leena Ketonen; Wafik Zaky
Journal:  J Neurooncol       Date:  2015-12-30       Impact factor: 4.130

Review 2.  Epileptic seizure in primary intracranial sarcoma: a case report and literature review.

Authors:  Yen-Ping Chen; Hsiu-Fen Lee; Tai-Tong Wong
Journal:  Childs Nerv Syst       Date:  2016-07-12       Impact factor: 1.475

3.  Giant cranial and cerebellar hemangioma treated with propranolol.

Authors:  Haggai Benvenisti; Liat Ben-Sira; Shlomi Constantini; Jonathan Roth
Journal:  Childs Nerv Syst       Date:  2014-12-04       Impact factor: 1.475

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.